Journey Medical (FBIO) Q2 2026 Earnings Call: Revenue Rises 23% as Emrosi Accelerates
Source Tradingkey
Key Takeaways
- Second-quarter 2026 revenue increased 23% year over year to $18.5 million, primarily driven by Emrosi, which generated $8.1 million in net revenue.
- Emrosi prescriptions reached approximately 36,000, up 20% sequentially from about 30,000 in Q1 2026. July prescriptions subsequently rose to approximately 14,000 from 13,000 in June.
- GAAP net loss narrowed to $300,000, or $0.01 per share, from $3.8 million, or $0.16 per share, in Q2 2025. Adjusted EBITDA improved to positive $2.9 million.
- Emrosi’s unique prescriber base exceeded 4,500, up more than 40% from approximately 3,200 at the end of 2025. June new prescriptions reached a monthly record of more than 5,300.
- High-quality formulary coverage for Emrosi increased from 34% of commercial lives in Q1 to approximately 38%. Management expects reimbursement progress to support further ASP improvement in the second half of 2026.
- Journey Medical expects to remain EBITDA positive for the rest of 2026 and continues to describe the year as a potential breakout period for revenue growth and profitability.
Key Financial Data
| Metric | Q2 2026 | Q2 2025 | Change / Commentary |
|---|---|---|---|
| Total revenue | $18.5 million | $15.0 million | Up 23% year over year |
| Emrosi net revenue | $8.1 million | — | Main revenue growth driver |
| Gross margin | 67% | 67% | Unchanged year over year |
| SG&A expense | $10.9 million | $11.9 million | Lower due primarily to prior-year Emrosi launch spending |
| GAAP net loss | $0.3 million | $3.8 million | Loss narrowed materially |
| GAAP loss per share | $0.01 | $0.16 | Basic and diluted |
| EBITDA | $1.4 million | $(1.9) million | Turned positive |
| Adjusted EBITDA | $2.9 million | $(0.5) million | Turned positive |
| Cash | $25.6 million | $24.1 million at Dec. 31, 2025 | Increased by $1.5 million |
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Recommended Articles
Financial Markets 2026: Volatility Catalysts in Gold, Silver, Oil, and Blue-Chip Stocks—A CFD Trader's OutlookGet a comprehensive financial market 2026 outlook exploring key economic drivers, volatility catalysts in gold, oil and stocks, and what the evolving economic outlook means for cfd trading strategies and risk management on global markets.
Get a comprehensive financial market 2026 outlook exploring key economic drivers, volatility catalysts in gold, oil and stocks, and what the evolving economic outlook means for cfd trading strategies and risk management on global markets.
As of the European session on August 11, gold prices (XAUUSD) briefly topped $4,400 intraday, reaching a high of $4,435.2, its highest level since June 5. However, gains subsequently narr
WTI declines below $82.50 as oil inventories rise far more than expectedWest Texas Intermediate (WTI), the US crude oil benchmark, is trading around $82.45 during the early Asian trading hours on Thursday. WTI declines on a larger-than-expected build in US crude oil inventories. Traders will closely monitor the developments surrounding US-Iran talks for fresh impetus.
West Texas Intermediate (WTI), the US crude oil benchmark, is trading around $82.45 during the early Asian trading hours on Thursday. WTI declines on a larger-than-expected build in US crude oil inventories. Traders will closely monitor the developments surrounding US-Iran talks for fresh impetus.
Here is what you need to know on Thursday, August 13:
WTI remains below $80.50 as traders monitor diplomatic efforts to reopen HormuzWest Texas Intermediate (WTI) oil price remains subdued for the third successive day, trading around $80.30 per barrel during the Asian hours on Friday. Crude oil prices edge lower as investors adopt a wait-and-see approach, closely monitoring diplomatic attempts to reopen the Strait of Hormuz.
West Texas Intermediate (WTI) oil price remains subdued for the third successive day, trading around $80.30 per barrel during the Asian hours on Friday. Crude oil prices edge lower as investors adopt a wait-and-see approach, closely monitoring diplomatic attempts to reopen the Strait of Hormuz.
